65,437 trials
Intercritical Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Diabetes Mellitus
Primary: Acceptability of NEAT! — 7 Participants
Multiple Sclerosis, Relapsing-Remitting
Primary: Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment…
Obesity · Insulin Resistance
Primary: Change From Baseline in Post-ischemic Dilatation — 9.6; 10.2; -1.2; -2.0 percent dilalation
Acute Gout Flare
Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…
Clopidogrel
Primary: Bleeding-related Re-hospitalization — 1; 1 participants
Anorexia Nervosa
Primary: Body Mass Index (BMI) (kg/m^2) — 19.66; 20.30; 19.66; 20.30 kg/m^2
Chest Pain
Primary: Frequency of Chest Pain Episodes — 1; 3 participants
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares
Adult Acute Myeloid Leukemia in Remission · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: 2 Year Disease Free Survival In Unrelated Donor Recipient Group — 40 percentage of participants
Hypertension
Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg — p=0.07
Schizophrenia
Primary: Effects of Nicotine Patch Compared With Placebo in Non- Smokers With Schizophrenia and Control Groups on Attention Measured by the Continuous Performance Test Identical…
Blood Loss After Primary Total Joint Arthroplasty · Need for Blood Transfusion After Total Joint Arthroplasty
Primary: Number of Participants Who Required Blood Transfusion — 4; 2 participants
Systemic Lupus Erythematosus
Primary: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) — 294; 291; 283; 260 Participants